

**Ustekinumab is rapid-acting and is an effective long-term
treatment for patients with active psoriatic arthritis:
real-world evidence from the non-interventional
SUSTAIN study**


Supplementary material

Jörg Wendler,¹ Nils Damann,² Marit Röcken,² Verena Teicher,² Maximilian Schuier,²
Frank Hamann,³ Holger Schwenke,⁴ Maren Sieburg,⁵ and Frank Behrens⁶

¹Rheumatologische Schwerpunktpraxis, Erlangen, Germany; ²Janssen-Cilag, Neuss, Germany; ³Gemeinschaftspraxis für internistische Rheumatologie, Leipzig, Germany
⁴Rheumatologisches MVZ, Dresden, Germany; ⁵Rheumatologische Facharztpraxis, Magdeburg, Germany, ⁶Rheumatologie und Fraunhofer Institut IM-TMP, Goethe-Universität, Frankfurt, Germany

Corresponding author: Nils Damann; NDamann@its.inj.com;


Supplementary figures



Supplementary Fig. 1 Tender and swollen joint counts in patients with axial involvement or with dactylitis

Mean tender joint count (a) and mean swollen joint count (b) in patients with axial involvement ($N = 31$), and mean tender joint count (c) and mean swollen joint count (d) in patients with dactylitis ($N = 56$). Data show the 95% CI


CI confidence interval, W week



Supplementary Fig. 2 Mean absolute change from baseline in (a) TJC and (b) SJC, with/without methotrexate, over time

Data show the 95% CI

CI confidence interval, MTX methotrexate, SJC swollen joint count, TJC tender joint count, W week



Supplementary Fig. 3 Mean absolute change from baseline in patient-assessed (a) sleep quality and (b) HAQ-DI, over time

Data show the 95% CI

HAQ-DI Health Assessment Questionnaire Disability Index, CI confidence interval

Supplementary tables

Supplementary Table 1 Baseline demographics

	All patients (N = 129)
Sex, <i>n</i> (%)	
Male	61 (47.3)
Female	68 (52.7)
Smoking status ^a , <i>n</i> (%)	
No	77 (65.3)
Yes	27 (22.9)
Ex-smoker	14 (11.9)
Missing	11
Alcohol consumption ^a , <i>n</i> (%)	
No	79 (70.5)
Yes	33 (29.5)
Missing	17
Age (years)	
<i>n</i>	129
Mean (SD)	54.3 (10.6)
Weight (kg)	
<i>n</i>	126
Mean (SD)	88.8 (18.7)
BMI (kg/m ²)	
<i>n</i>	126
Mean (SD)	30.0 (5.6)

BMI body mass index, *CRF* case report form, *SD* standard deviation

^aIf 'not specified' was documented in the CRF then the data are displayed as 'missing'

Supplementary Table 2 Reason for discontinuation of prior therapy

	All patients (N = 129)		All patients (N = 129)
Diclofenac, n (%)		Ciclosporin, n (%)	
Lack of efficacy	4 (22.2)	Lack of efficacy	7 (53.8)
Lack of tolerability	5 (27.8)	Lack of tolerability	4 (30.8)
Lack of efficacy & tolerability	0 (0)	Lack of efficacy & tolerability	0 (0)
Unknown	9 (50.0)	Unknown	2 (15.4)
Missing	6		
Ibuprofen, n (%)		Leflunomide, n (%)	
Lack of efficacy	9 (37.5)	Lack of efficacy	12 (42.9)
Lack of tolerability	1 (4.2)	Lack of tolerability	11 (39.3)
Lack of efficacy & tolerability	1 (4.2)	Lack of efficacy & tolerability	4 (14.3)
Unknown	13 (54.2)	Unknown	1 (3.6)
Missing	17	Missing	2
Meloxicam, n (%)		Methotrexate, n (%)	
Lack of efficacy	2 (100.0)	Lack of efficacy	28 (34.6)
Lack of tolerability	0 (0)	Lack of tolerability	41 (50.6)
Lack of efficacy & tolerability	0 (0)	Lack of efficacy & tolerability	6 (7.4)
Unknown	0 (0)	Unknown	6 (7.4)
Missing	2	Missing	21
Naproxen, n (%)		Sulfasalazine, n (%)	
Lack of efficacy	2 (50.0)	Lack of efficacy	11 (57.9)
Lack of tolerability	0 (0)	Lack of tolerability	4 (21.1)
Lack of efficacy & tolerability	0 (0)	Lack of efficacy & tolerability	0 (0)
Unknown	2 (50.0)	Unknown	4 (21.1)
		Missing	1
Indometacin, n (%)		Adalimumab, n (%)	
Lack of efficacy	0 (0)	Lack of efficacy	24 (61.5)
Lack of tolerability	0 (0)	Lack of tolerability	11 (28.2)
Lack of efficacy & tolerability	0 (0)	Lack of efficacy & tolerability	1 (2.6)
Unknown	2 (100)	Unknown	3 (7.7)

COX-2 inhibitor (Coxibs), <i>n</i> (%)		Certolizumab, <i>n</i> (%)	
Lack of efficacy	7 (43.8)	Lack of efficacy	4 (66.7)
Lack of tolerability	2 (12.5)	Lack of tolerability	1 (16.7)
Lack of efficacy & tolerability	0 (0)	Lack of efficacy & tolerability	1 (16.7)
Unknown	7 (43.8)	Unknown	0 (0)
Missing	3	Etanercept, <i>n</i> (%)	
Other NSAID, <i>n</i> (%)		Lack of efficacy	22 (71.0)
Lack of efficacy	2 (28.6)	Lack of tolerability	5 (16.1)
Lack of tolerability	0 (0)	Lack of efficacy & tolerability	2 (6.5)
Lack of efficacy & tolerability	0 (0)	Unknown	2 (6.5)
Unknown	5 (71.4)	Missing	1
Missing	3	Golimumab, <i>n</i> (%)	
Methylprednisolone, <i>n</i> (%)		Lack of efficacy	13 (72.2)
Lack of efficacy	0 (0)	Lack of tolerability	4 (22.2)
Lack of tolerability	0 (0)	Lack of efficacy & tolerability	1 (5.6)
Lack of efficacy & tolerability	0 (0)	Unknown	0 (0)
Unknown	1 (100)	Infliximab, <i>n</i> (%)	
Prednisone/Prednisolone, <i>n</i> (%)		Lack of efficacy	1 (25.0)
Lack of efficacy	5 (16.7)	Lack of tolerability	1 (25.0)
Lack of tolerability	4 (13.3)	Lack of efficacy & tolerability	0 (0)
Lack of efficacy & tolerability	0 (0)	Unknown	2 (50.0)
Unknown	21 (70.0)	Other, <i>n</i> (%)	
Missing	7	Lack of efficacy	12 (57.1)
Other systemic corticosteroid, <i>n</i> (%)		Lack of tolerability	6 (28.6)
Lack of efficacy	0 (0)	Lack of efficacy & tolerability	1 (4.8)
Lack of tolerability	0 (0)	Unknown	2 (9.5)
Lack of efficacy & tolerability	0 (0)	Missing	2
Unknown	2 (100)		
Missing	1		

100% = Number of patients with the respective medication and a reason given

The table shows only medications for which at least once a reason is given

COX-2 cyclooxygenase-2, NSAID non-steroidal anti-inflammatory drug

Supplementary Table 3 Rate of patients reaching single minimal disease activity criterion by minimal disease activity status

	MDA not achieved	MDA achieved
Single criterion reached at week 28 (<i>N</i> = 67/47 ^a), <i>n</i> (%)		
TJC ≤ 1	25 (37.3)	43 (91.5)
SJC ≤ 1	42 (62.7)	47 (100)
PASI ≤ 1 or BSA ≤ 3%	45 (67.2)	37 (78.7)
Patient pain VAS ≤ 15	3 (4.5)	34 (72.3)
Patient global disease activity VAS ≤ 20	4 (6.0)	38 (80.9)
HAQ-DI ≤ 0.5	9 (13.4)	43 (91.5)
Tender enthesal points ≤ 1	45 (67.2)	36 (76.6)
Single criterion reached at week 52 (<i>N</i> = 63/47 ^a), <i>n</i> (%)		
TJC ≤ 1	29 (46.0)	43 (91.5)
SJC ≤ 1	45 (71.4)	46 (97.9)
PASI ≤ 1 or BSA ≤ 3%	49 (77.8)	41 (87.2)
Patient pain VAS ≤ 15	0 (0)	32 (68.1)
Patient global disease activity VAS ≤ 20	6 (9.5)	34 (72.3)
HAQ-DI ≤ 0.5	3 (4.8)	44 (93.6)
Tender enthesal points ≤ 1	37 (58.7)	35 (74.5)

BSA body surface area, *HAQ-DI* health assessment questionnaire disability index, *MDA* minimal disease activity, *PASI* Psoriasis Area and Severity Index, *SJC* swollen joint count, *TJC* tender joint count, *VAS* visual analog scale

^aNumber of patients with MDA not achieved/achieved at this visit

Supplementary Table 4 Minimal disease activity in patients with and without concomitant methotrexate treatment

	Without MTX (N = 54)	With MTX (N = 59)
MDA reached at week 28, n (%)	17 (31.5)	19 (32.2)
MDA reached at week 52, n (%)	20 (37.0)	18 (30.5)
<i>Percentage base is the number of patients without MDA at baseline in the respective group</i>		

MDA minimal disease activity, MTX methotrexate